十一、参考文献
1. Turnidge J and Paterson DL. Setting and revising antibacterial
susceptibility breakpoints [J]. Clinical Microbiology Reviews, 2007, 20:
391-408. 2. Turnidge J, Kahlmeter G and Kronvall G. Statistical characterization of
bacterial wild-type MIC value distributions and the determination of
epidemiological cut-off value [J]. Clinical Microbiology and Infection, 2006,
12: 418-425. 3. Owens RC and Shorr AF. Rational dosing of antimicrobial agents:
pharmacokinetic and pharmacodynamics strategies [J]. Am J Health-Syst Pharm,
2009, 66（Suppl
4）: S23-30. 4. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-
pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore [J].
Clin Infec Dis, 2007, 44: 79-86. 5. Amsterdam D, edited. Antibiotics in Laboratory Medicine [M]. Wolters
Kluwer, Philadelphia, 6th edition, 2015, p9-16. 6. Xiao XM, Xiao YH. Pharmacokinetics/pharmacodynamics of antofloxacin
hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection[J].
Acta Pharmacol Sin, 2008, 29:1253-1260. 7. 史军.
药物动力学和药效动力学在抗菌药物新药开发和临床治疗上的应用. 中国临床药理学与治疗学, 2007, 12:121-133. 8. Clinical and Laboratory Standards Institute. 2008 Development of in
vitro susceptibility testing criteria and quality control parameters: approved
guideline-3rd ed. [M]. CLSI document M23-A3 CLSI, Wayne, PA.
附：工作流程及建立PK/PD界值流程
附 工作流程及建立PK/PD界值流程
|
